Novartis

KYMRIAH

Manufacturer:

Novartis

Kymriah HCPCS:

Q2042

HCPCS Code Descriptor:

Tisagenlecleucel, up to 600 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose

Category:

Q Code

Kymriah NDCs:

00078-0846-19, 00078-0958-19

Primary Type:

Oncology

Generic/Specialty Status:

Single-Source

Route of Administration:

Intravenous

Potential NDC Listing Errors:

Our team has identified potential listing errors/discrepancies with the following NDCs:

00078-0846-19, 00078-0958-19

About Kymriah:

KYMRIAH is an Oncology drug manufactured by Novartis and administered via the Intravenous route of administration. The Q Code: Q2042 is aligned to the drug KYMRIAH.

ACCESS PRICING AND MORE BY REGISTERING

Q2042 Added Date:

January 1, 2019

Q2042 Effective Date:

January 1, 2019

Q2042 Termination Date:

HCPCS Active

We have not yet identified a manufacturer source of Kymriah billing and coding information.
Kymriah patient assistance information can be found through KYMRIAH CARES at the URL: https://www.us.kymriah.com/acute-lymphoblastic-leukemia-children/patient-support/support-resources-for-kymriah/
KYMRIAH prescribing information can be found at the link below:
Information regarding KYMRIAH’s side effects can be found at MedlinePlus